: Amgen’s cancer-drug pipeline looks promising despite FDA setback, analysts say

Strong oncology, obesity, and cardiovascular drug candidates behind rating upgrade

Previous post Economic Report: U.S. producer price inflation comes in a little hotter in September, highest annual rate in five months
Next post Deep Dive: Dividend stocks are dirt cheap. It may be time to back up the truck.